Alfred Garfall
University of Pennsylvania
H-index: 37
North America-United States
Top articles of Alfred Garfall
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma | Transplantation and Cellular Therapy | Elise A Chong Emeline R Chong Dylan Therwhangher Sunita D Nasta Daniel J Landsburg | 2024/3/16 |
Human IL-6 fosters long-term engraftment of patient derived disease-driving myeloma cells in immunodeficient mice | bioRxiv | Zainul S Hasanali Alfred Garfall Lisa Burzenski Leonard Shultz Yan Tang | 2024 |
Teclistamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase II MajesTEC-1 study | Clinical Lymphoma Myeloma and Leukemia | Thomas G Martin Philippe Moreau Saad Z Usmani Alfred Garfall María-Victoria Mateos | 2024/3/1 |
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network | Shaji K Kumar Natalie S Callander Kehinde Adekola Larry D Anderson Muhamed Baljevic | 2024/1/1 |
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines | Blood Advances | Guido Ghilardi Luca Paruzzo Jakub Svoboda Elise A Chong Alexander A Shestov | 2024/2/13 |
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel | Journal of Hematology & Oncology | Guido Ghilardi Luca Paruzzo Vrutti Patel Jakub Svoboda Emeline R Chong | 2024/4/22 |
New biological therapies for multiple myeloma | Alfred L Garfall | 2024/1/29 | |
Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma | Zainul S Hasanali Beatrice Razzo Sandra P Susanibar-Adaniya Alfred L Garfall Edward A Stadtmauer | 2024/4/1 | |
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy | Nature Medicine | Guido Ghilardi Joseph A Fraietta James N Gerson Vivianna M Van Deerlin Jennifer JD Morrissette | 2024/1/24 |
CAR T-cell immunotherapy in minority patients with lymphoma | NEJM Evidence | Guido Ghilardi Staci Williamson Raymone Pajarillo Luca Paruzzo Linhui Chen | 2024/3/26 |
Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy | Blood | Yan Tang Wei Liu Siddhant Kadu Omar Johnson Zainul S Hasanali | 2024/1/11 |
Progressive multifocal leukoencephalopathy in multiple myeloma | European Journal of Haematology | Brian W Hoeynck Adam D Cohen Edward A Stadtmauer Sandra P Susanibar‐Adaniya Dan T Vogl | 2023/3 |
Outcomes of diffuse large/high grade B cell lymphoma patients following receipt of autologous stem transplantation or chimeric antigen receptor‐modified T cells | Hematological Oncology | DJ Landsburg SD Nasta J Svoboda JN Gerson SJ Schuster | 2023/6 |
P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY | HemaSphere | Manisha Bhutani Alfred Garfall Katarina Uttervall Saad Z Usmani Lionel Karlin | 2023/8/1 |
Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy | Blood | Adam D Cohen Wei-Ting Hwang Sandra Susanibar-Adaniya Dan T Vogl Alfred L Garfall | 2023/11/28 |
CO129 Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy (RWPC) for Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple … | Value in Health | A Krishnan A Nooka A Chari AL Garfall T Martin | 2023/12/1 |
Understanding Infection Risk with Anti-BCMA Bispecific Antibodies | Blood Cancer Discovery | Alfred L Garfall Edward A Stadtmauer | 2023/11/1 |
Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy | Blood Cancer Discovery | Alfred L Garfall Adam D Cohen Sandra P Susanibar-Adaniya Wei-Ting Hwang Dan T Vogl | 2023/3/1 |
Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in … | Niels WCJ van de Donk Alfred L Garfall Lotfi Benboubker Katarina Uttervall Kaz Groen | 2023/6/1 | |
P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) | HemaSphere | Surbhi Sidana Philippe Moreau Alfred Garfall Manisha Bhutani Albert Oriol | 2023/8/1 |
